Oxford/AstraZeneca Vaccine Shows 70% Efficacy As Company Prepares Approval Filings

Vaccine Will Be 'Affordable And Globally Available'

23 Nov 2020

Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.

Doctor's hand holding bottle vaccine Covid-19 from storage box. Medication treatment concept. — Three COVID-19 vaccines have now shown positive Phase III results • Source: Shutterstock

Following the promising results from trials of the COVID-19 vaccine developed by AstraZeneca PLC and the University of Oxford, the UK company says it will now prepare regulatory submissions around the world, which could result in the vaccine being granted emergency use authorization before the end of the year.

The first interim analysis of the Phase III data showed that AZD1222 achieved a 70% efficacy rate, while an "intriguing"...